Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group.

NC, Tassopoulos; R, Volpes; G, Pastore; J, Heathcote; M, Buti; RD, Goldin; S, Hawley; J, Barber; L, Condreay; DF, Gray

doi:10.1002/hep.510290321

Public

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group.

Shared by NobleBlocks on Mar 1, 1999 • 12:00 AM UTC

Authors:

Tassopoulos NC

Volpes R

Pastore G

Abstract

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n = 60) ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!